Szekanecz Z, Bordán E, Szabó Z, Szegedi G
Debreceni Orvostudományi Egyetem, III. sz. Belgyógyászati Klinika.
Orv Hetil. 1998 Feb 1;139(5):227-34.
Angiogenesis, the production of new blood vessels, plays an important role in a number of physiological and pathological processes, such as development, tissue repair, atherosclerosis, ischemic heart diseases, inflammation and tumor progression. A number of mediators including cytokines, heparin-dependent and -independent growth factors, proteolytic enzymes, extracellular matrix components, cellular adhesion molecules and others, have been implicated in angiogenesis. Certain angiostatic cytokines, growth factor antagonists, steroids, protease inhibitors, antibiotics, antirheumatic drugs, tissue-derived inhibitors and others inhibit neovascularization. Angiogenesis research has important clinical relevance, as targeting angiogenic and angiostatic processes by using angiogenesis inhibitors, receptor antagonists, antibodies, enzyme inhibitors, tumor suppressor genes and other forms of gene therapy, may be a potential therapeutic tool in "angiogenic diseases".
血管生成,即新血管的形成,在许多生理和病理过程中发挥着重要作用,如发育、组织修复、动脉粥样硬化、缺血性心脏病、炎症和肿瘤进展。包括细胞因子、肝素依赖性和非依赖性生长因子、蛋白水解酶、细胞外基质成分、细胞黏附分子等在内的多种介质与血管生成有关。某些血管生成抑制细胞因子、生长因子拮抗剂、类固醇、蛋白酶抑制剂、抗生素、抗风湿药物、组织衍生抑制剂等可抑制新血管形成。血管生成研究具有重要的临床意义,因为通过使用血管生成抑制剂、受体拮抗剂、抗体、酶抑制剂、肿瘤抑制基因和其他形式的基因治疗来靶向血管生成和血管生成抑制过程,可能是治疗“血管生成性疾病”的一种潜在治疗工具。